GLP-3
Recommended Dosage
Common wellness/research protocol: Start with 1–2 mg subcutaneously once weekly for the first 4 weeks (titration phase). Increase every 4 weeks as tolerated: 4 mg, then 8 mg, up to a maintenance dose of 8–12 mg once weekly. Lower starting doses (e.g., 0.5–2 mg) and slower escalation improve tolerability.
Other reported ranges: Maintenance doses in trials range from 4 mg to 12 mg weekly, with 8–12 mg associated with the strongest effects. Injections are given on the same day each week. Titration typically spans 12–16 weeks to reach target dose.
Reconstitution example (for typical research vials, e.g., 10–20 mg): Add 2 mL bacteriostatic water (yielding 5–10 mg/mL depending on vial size). Use an insulin syringe and calculate volume precisely for the target dose (e.g., at 10 mg/mL: 1 mg = 0.1 mL / 10 units; 4 mg = 0.4 mL / 40 units). Subcutaneous injection (abdomen, thigh, or upper arm) is the standard route.
Dosing is highly individualized based on goals (weight loss, glycemic control, metabolic support), tolerance, body weight, and response—consult a qualified healthcare provider experienced with incretin therapies for personalized guidance and monitoring. This is for informational purposes only.
